TABLE 1.

Determination of MICs in different isolates of C. neoformans and C. gattii using fenbendazole (FBZ), fluconazole (FCZ), and amphotericin B as antifungals^a

Isolateb	Origin	MIC (μg/ml) for:
		FBZ	FCZ	AmB
C. neoformans H99	Clinical	0.012	2.0	0.5
C. neoformans 162	Clinical	0.012	8.0	0.5
C. neoformans 191	Clinical	0.012	8.0	0.25
C. neoformans 186	Clinical	0.012	4.0	0.25
C. neoformans 161	Clinical	0.012	4.0	0.5
C. neoformans 160	Clinical	0.012	4.0	0.5
C. neoformans 139	Clinical	0.012	4.0	0.5
C. neoformans 118	Clinical	0.012	8.0	0.25
C. neoformans 116	Clinical	0.012	8.0	0.5
C. neoformans 115	Clinical	0.012	4.0	0.5
C. neoformans 222	Clinical	0.012	2.0	0.5
C. neoformans 223	Clinical	0.012	4.0	0.5
C. neoformans 218	Clinical	0.012	2.0	0.25
C. gattii R265	Clinical	0.012	8.0	0.5
C. gattii 367	Environmental	0.012	8.0	0.25
C. gattii 368	Environmental	0.012	16.0	0.25
C. gattii 365	Environmental	0.012	4.0	0.5
C. krusei ATCC 6258c	Not applicable	>1.536	>64	0.25
C. parapsilosis ATCC 22019c	Not applicable	>1.536	1.0	0.25

^aAs determined by EUCAST, growth inhibition measurements corresponded to 50% for FLZ and 90% for AmB. FBZ inhibition rates shown in the table correspond to 90%. Identical values were obtained when 50% inhibition rates were determined for FBZ (data not shown).

^bStrain numbers were attributed by the Collection of Pathogenic Fungi of Fiocruz. For details, see http://cfp.fiocruz.br/index.

³The C. krusei and C. parapsilosis isolates were used as controls of antifungal activity as preconized by EUCAST. The MIC results obtained with these isolates were at the expected range (47).